Free cash flow burn has plateaued between -$13.9M and -$25.3M per quarter (recently -$16.1M in 2026Q2), with near-zero cumulative capex under $700K and a 0.61 net-loss-to-operating-cash ratio suggesting non-cash items and a $2.4M working capital release are temporarily cushioning outflows.
Fulcrum Therapeutics, Inc. (FULC) cash flow statement — 9-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 |
|---|
| Cash from Operations | -64.97M | -60.06M | -2.22M | -90.97M | -97.05M | -78.48M | -53.66M | -39.48M | -22.56M | -20.07M |
| Operating CF Margin % | - | - | -2.77% | -3242.96% | -1530.27% | -409.53% | -608.13% | - | - | - |
| Operating CF Growth % | -33.48% | -2608.07% | 97.56% | 6.27% | -23.67% | -46.26% | -35.89% | -75% | -12.39% | - |
| Net Income | -76.34M | -74.88M | -9.72M | -97.33M | -109.87M | -80.85M | -70.82M | -82.68M | -32.59M | -22.96M |
| Depreciation & Amortization | 901K | 1.39M | 1.59M | 2.17M | 2.41M | 2.52M | 2.38M | 2.05M | 1.34M | 715K |
| Stock-Based Compensation | 12.37M | 12.47M | 14.55M | 14.8M | 13.35M | 11.07M | 7.35M | 4.22M | 2.16M | 1.37M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 1.93M | 0 | 0 | 0 |
| Other Non-Cash Items | 4.66M | -2.95M | -4.39M | -5.99M | 152K | 673K | -2M | 25.59M | 4.87M | 2.59M |
| Working Capital Changes | -6.55M | 3.91M | -4.25M | -4.61M | -3.09M | -11.89M | 7.5M | 11.33M | 6.52M | 804K |
| Change in Receivables | 0 | 2.1M | -1.56M | -308K | 2.5M | -500K | -2M | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 1.25M | 229K | 0 | 0 | 0 |
| Change in Payables | -2.19M | 428K | -1.59M | -853K | -1.18M | 973K | 1.77M | 803K | -20K | 208K |
| Cash from Investing | -34.35M | 30.72M | 32.23M | -36.69M | 12.41M | -129.67M | -57.14M | -944K | -8.98M | -1.91M |
| Capital Expenditures | -275K | -314K | -278K | -508K | -1.96M | -1.71M | -1.34M | -853K | -8.98M | -1.91M |
| CapEx % of Revenue | - | - | 0.35% | 18.11% | 30.95% | 8.94% | 15.21% | - | - | - |
| Acquisitions | 900K | 0 | 0 | 0 | -14.38M | 127.96M | 55.8M | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 14.38M | -127.96M | -55.8M | -91K | 0 | 0 |
| Cash from Financing | 168.54M | 168.67M | 2.75M | 118.12M | 84.32M | 186.51M | 71.13M | 64.34M | 105.03M | 17.66M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | -18K | -50K | -45K | -70K | 0 |
| Equity Issued (Net) | 168.88M | 168.67M | 2.75M | 117.34M | 80.8M | 182.86M | 69.95M | 64.14M | 105.08M | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -333K | 0 | 0 | 777K | 3.52M | 3.67M | 1.24M | 249K | 12K | 17.66M |
| Net Change in Cash | 69.22M | 139.32M | 32.76M | -9.54M | -314K | -21.64M | -39.66M | 23.92M | 73.48M | -4.32M |
| Free Cash Flow | -65.24M | -60.38M | -2.5M | -91.47M | -99.01M | -80.19M | -55M | -40.34M | -31.54M | -21.98M |
| FCF Margin % | - | - | -3.12% | -3261.07% | -1561.23% | -418.47% | -623.34% | - | - | - |
| FCF Growth % | -7.99% | -2319.03% | 97.27% | 7.62% | -23.47% | -45.81% | -36.35% | -27.88% | -43.49% | - |
| FCF per Share | -0.85 | -0.95 | -0.04 | -1.49 | -2.20 | -2.27 | -2.17 | -1.78 | -1.86 | -1.30 |
| FCF Conversion (FCF/Net Income) | 0.85x | 0.80x | 0.23x | 0.93x | 0.88x | 0.97x | 0.76x | 0.48x | 0.69x | 0.87x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying FULC stock.
Fulcrum Therapeutics, Inc. (FULC) generated $-60.1M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Fulcrum Therapeutics, Inc. (FULC) reported negative free cash flow of $60.4M in 2025, indicating capital requirements exceeded cash from operations.
Fulcrum Therapeutics, Inc. (FULC) spent $0.3M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
Key Metrics
Top Statement Risk
Non-recurring milestone revenue dependency
Metrics are mathematically derived from official filings.
Loss-to-Cash Conversion Gap Widens
The divergence between Fulcrum's net loss and operating cash flow widened materially in 2026Q2, with the $26.2M loss translating to only $16.0M of cash burn, a 0.61 ratio suggesting non-cash charges and working capital timing are masking the underlying cash cost of operations, per SEC filings.
For most quarters in the dataset, operating cash flow tracked net income closely, with OCF/NI ratios clustering between 0.72 and 1.01, indicating that reported losses are a reasonable proxy for cash burn. The 2026Q2 quarter breaks this pattern: the $26.2M net loss dwarfed the $16.0M cash outflow, yet known non-cash items (SBC of $3.3M, D&A of $0.2M) and the $2.4M working capital release account for only about $5.9M of the $10.2M gap. This suggests additional unexplained non-cash charges or accrual reversals in the period, and investors should scrutinize the reconciliation to determine whether the loss represents a genuine step-up in underlying cost intensity.
Cash Burn Plateaus Without Structural Relief
Excluding the anomalous 2024Q2 milestone quarter, Fulcrum's free cash flow burn has remained stubbornly persistent, ranging from -$13.9M to -$25.3M quarterly with recent periods clustering near -$16-19M, indicating no structural improvement in the cash cost of its pre-revenue R&D platform, as reported in SEC filings.
The 2024Q2 quarter, which generated $58.9M of positive free cash flow on the back of a one-time milestone, is the sole exception in an otherwise uniformly negative series; every other quarter in the ten-quarter window burned cash. The most recent five quarters (2025Q2 through 2026Q2) show FCF losses of -$13.9M, -$15.3M, -$17.0M, -$14.3M, -$18.8M, and -$16.1M, which while fluctuating, show no downward trajectory despite the earlier reported decline in R&D spend from $19.3M to $12.4M. This suggests that cost reductions have been offset by other outflows or non-operating charges, reinforcing the concern that the 2024Q2 windfall masked a structurally unprofitable operating model with no clear path to cash-flow breakeven absent new milestone revenue.
Near-Zero Capex Signals Asset-Light Fragility
Fulcrum's capital expenditures have been virtually nonexistent, totaling less than $700K across all ten quarters, confirming an asset-light research model with no manufacturing infrastructure; meanwhile depreciation and amortization declined from $479K to $216K quarterly, suggesting the existing fixed asset base is consumed without replenishment, per recent financial statements.
With capex ranging from $0 to $231K per quarter and representing a negligible fraction of the cash burn, Fulcrum operates almost entirely on human capital and outsourced capabilities rather than owned production assets. The declining D&A trajectory — from $479K in 2024Q1 to $216K in 2026Q2, a roughly 55% decline — is consistent with a small and aging fixed asset base that is being depreciated without meaningful reinvestment. While this keeps near-term cash outflows low, it also means Fulcrum has no proprietary manufacturing capacity, and any transition to commercial-scale production would require capital investment not reflected in the current cash flow profile; this warrants monitoring as pipeline assets approach potential inflection points.
Working Capital Swings Offer Limited Cash Insight
Working capital movements at Fulcrum have been volatile but modest, swinging from -$3.3M to +$2.4M in recent quarters, suggesting collections and payables are not the primary driver of cash burn; the +$2.4M release in 2026Q2 may have temporarily cushioned operating outflow, based on reported figures.
The working capital line shows no discernible trend and its magnitude rarely exceeds $3M in any direction, indicating that for a pre-revenue research-stage company, neither inventory management nor receivables collection materially shapes the cash trajectory. The +$2.4M working capital release in 2026Q2 and the +$2.3M inflow in 2025Q3 represent occasional tailwinds, while the -$3.3M drag in 2026Q1 and -$2.1M in 2024Q4 were occasional headwinds. These fluctuations are second-order relative to the recurring $14-19M quarterly operating burn, and investors should focus on the structural R&D and SG&A cost base rather than working capital dynamics when modeling FULC's cash runway.
SBC Masks True Economic Dilution
Stock-based compensation of $2.5M to $4.3M per quarter, totaling roughly $33.2M over ten quarters, represents a recurring non-cash charge that flatters Fulcrum's operating cash flow relative to net income and dilutes shareholders without appearing in the cash burn figures, as disclosed in SEC filings.
Because SBC is added back in the operating cash flow calculation, Fulcrum's OCF understates the true economic cost of compensating employees with equity. Cumulative SBC of approximately $33.2M over the ten-quarter period is substantial relative to the recurring quarterly burn rate of $14-19M, implying that the effective economic dilution is meaningfully larger than the reported cash burn alone would suggest. For a pre-revenue biotech where equity is the primary currency for talent retention, the persistence of SBC at $3-4M per quarter raises questions about whether the reported cash runway adequately reflects the full shareholder cost structure, and investors should model dilution alongside the cash burn trajectory.